J. Gustav Smith

Country flagSweden

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (24)

Despite the importance of the gut microbiome to health, the role of human genetic variation in shaping its composition remains poorly understood. Here we report genome-wide association analyses of harmonized metagenomic data from 16,017 adults in four Swedish population-based studies, with replication in 12,652 people from the Norwegian HUNT study. We identified variants in the OR51E1–OR51E2 locus, encoding sensors for microbiome-derived fatty acids, associated with microbial richness. We further identified 15 study-wide significant genetic associations ( P < 5.4 × 10 −11 ) involving eight loci and 14 common bacterial species, of which 11 associations at six loci were replicated. The results confirm previously reported associations at LCT , ABO and FUT2 , and provide evidence for new loci MUC12 , CORO7–HMOX2 , SLC5A11 , FOXP1 and FUT3–FUT6 , with supporting data from metabolomics and gene expression analyses. Our findings link gut microbial variation genetically to gastrointestinal functions, including enteroendocrine fatty acid sensing, bile composition and mucosal layer composition.

Year:

2026

Year:

2026

Aortic stenosis (AS) is a common valvular heart disease and has no pharmacological therapies. We performed a multi-ancestry genome-wide association meta-analysis of 86,864 AS cases among 2,853,408 individuals, discovering 241 autosomal independent risk loci and 3 X chromosome risk loci. We additionally performed sex-stratified and ancestry-stratified genome-wide association studies (GWASs), identifying an additional 5 sex-specific risk loci, 11 risk loci in European ancestry individuals and 1 risk locus in African ancestry individuals. We also performed a transcriptome-wide association study using expression quantitative trait loci from human aortic valves, discovering 54 new genes for which genetically predicted expression influences the risk of AS. We then generated a new polygenic risk score for AS. Finally, we performed gene silencing experiments targeting biologically relevant genes identified by our GWAS. Silencing of CMKLR1 and LTBP4 in human valvular interstitial cells substantially decreased mineralization, implicating a role for polyunsaturated fatty acids and transforming growth factor β signaling in AS.

Year:

2026

Year:

2026

BACKGROUND: NPs (natriuretic peptides) are bioactive hormones crucial for regulating blood pressure, glucose homeostasis, and lipid metabolism. Despite the high heritability of circulating NP levels, the genetic determinants of NP regulation, particularly across ancestries and sexes, remain poorly understood. The objective of the current study was to identify genetic variants associated with NT-proBNP (N-terminal pro-B-type NP) levels in a multiancestry study population. METHODS: Whole genome sequencing and array-based data from 81 213 individuals without heart failure were analyzed from the Trans-Omics for Precision Medicine cohorts, UK Biobank, All of Us Research Program, and REGARDS (Reasons for Geographic and Racial Differences in Stroke) study to identify common, rare, and structural variants associated with NT-proBNP levels. The main outcome of the study was rank-based inverse normal and standardized NT-proBNP levels. Genetic associations with NT-proBNP were examined, followed by gene prioritization, transcriptome-wide association studies, colocalization, and rare variant analyses. RESULTS: Nine novel loci and 3 previously reported loci were identified to be associated with NT-proBNP levels. Novel structural variants were detected across 12 loci. Similar effect sizes were observed for both common and rare variants. Key genes such as BAG3 (10q26.11) and SLC39A8 (4q24) were identified through gene prioritization, with prior animal models supporting their therapeutic relevance. Rare variant analysis identified 6 masks with significant associations, specifically non-coding masks, suggesting regulatory modulation of NT-proBNP. CONCLUSIONS: This study identifies novel common, rare, and structural variants associated with NT-proBNP levels, highlighting the contribution of both coding and regulatory non-coding variation. These findings advance our understanding of the genetic architecture of NT-proBNP and may inform future cardiometabolic therapeutic strategies.

Year:

2026

Year:

2026

Year:

2026

Background and aims Guideline-directed medical therapy (GDMT) for heart failure (HF) is underutilized in primary care, particularly among older adults with chronic stable HF. This prospective quality improvement study, Heart Failure in Southern Sweden (HISS), evaluated the impact of a cross-disciplinary implementation project combining cardiology and primary care expertise to enhance GDMT adherence and reduce healthcare contacts. Methods Twenty primary health care centres in southern Sweden participated, recruiting 587 patients diagnosed with HF (mean age 79 years) between 2021 and 2023. The intervention involved case-based educational conferences with cardiologists and general practitioners, individualized treatment recommendations, and follow-up monitoring. Medication use and healthcare contacts were assessed 6 months before and after the intervention. Results GDMT use (defined as quadruple therapy according to the 2022 guidelines) increased from 20.8% at baseline to 37.7% post-intervention (P < .001) among patients with HF with reduced ejection fraction (HFrEF), and from 12.4% to 17.8% (P = .020) among patients with mildly reduced ejection fraction (HFmrEF). The uptake of sodium–glucose co-transporter-2 inhibitors (SGLT2i) improved significantly across all HF types, while angiotensin receptor-neprilysin inhibitors (ARNI) increased among HFrEF patients. Beta-blocker use declined in patients with HF with preserved ejection fraction. The total number of ambulatory healthcare contacts decreased following the intervention, while the hospitalizations remained unchanged. Conclusions The HISS study demonstrates that a cross-disciplinary, case-based educational intervention was associated with improved GDMT adherence (especially SGLT2i and ARNI) and reduced ambulatory healthcare utilization in primary care patients with chronic stable HF. These findings underscore the importance of bridging the gap between specialist and primary care to optimize HF management.

Year:

2026

Context Type 2 diabetes is a growing global concern with serious complications, including kidney damage and cardiovascular morbidity and mortality. Monitoring albuminuria, which is associated with these complications, is crucial in optimal diabetes management. Gut microbiota composition has been suggested to impact albuminuria, but large studies with granular data are lacking. Methods We investigated the relationship between 1002 gut microbial species, 1308 plasma metabolites, and albuminuria in 752 participants with type 2 diabetes from the Swedish CArdioPulmonary BioImage Study (SCAPIS). To determine the relative abundance of species, we employed deep shotgun metagenomic sequencing of fecal samples. Plasma metabolites were analyzed using mass spectrometry-based methods. Results We identified 3 species that were associated with albuminuria, including Sellimonas intestinalis, Eggerthellales sp., and Ellagibacter isourolithinifaciens. Two of these species were replicated in an independent prediabetic population (n = 3423) in SCAPIS. In total, 36 annotated metabolites were associated with the 3 albuminuria-signature species. Functional mapping of the signature species suggests a role in the regulation of the metabolites of imidazole propionate and trigonelline, which have previously been reported to play roles in the progression of albuminuria. Conclusion These findings provide additional evidence of the potential impact of microbial species and contribute to our understanding of the complex relationship between the gut microbiome, plasma metabolites, and albuminuria in individuals with diabetes.

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (45)

Koen Dekkers

Uppsala University

SWEDEN
View details

Daniel Engelbertsen

Lund University

SWEDEN
View details

Andrea Ganna

Professor at University of Helsinki

University of Helsinki

FINLAND
View details

Radoslaw Debiec

NIHR Academic Clinical Lecturer in Platform Science

University of Leicester

UNITED KINGDOM
View details

Annika Rosengren

University of Gothenburg

SWEDEN
View details

Martin Lindgren

Associate professor

University of Gothenburg

SWEDEN
View details

Tiscar Graells

Karolinska Institutet

SWEDEN
View details

Linda Johnson

Associate Professor

Lund University

SWEDEN
View details

Ruth Loos

The Charles Bronfman Professor in Personalized Medicine

Københavns Universitet

DENMARK
View details

Isabel Goncalves

Lund University

SWEDEN
View details

Veronica Milos Nymberg

Associate professor

Lund University

SWEDEN
View details

Kristina Sundquist

Lund University

SWEDEN
View details

Kristina Vukusic

University of Gothenburg

SWEDEN
View details

Tiinamaija Tuomi

Professor

University of Helsinki

FINLAND
View details

Julian D Gillmore

University College London

UNITED KINGDOM
View details

Harry Björkbacka

Lund University

SWEDEN
View details

Johan Sundstrom

Conjoint professor

University of New South Wales

AUSTRALIA
View details

Carlo Maj

Head of Bioinformatics | Research Group Leader – Genetic Epidemiology

University of Marburg

GERMANY
View details

Pontus Nordenfelt

Lund University

SWEDEN
View details

Susanne J Nielsen

University of Gothenburg

SWEDEN
View details

Gunnar Engström

Professor

Umeå Universitet Medicinska fakulteten

SWEDEN
View details

Quinn Wells

Associate Professor of Medicine

Vanderbilt University Medical Center

UNITED STATES
View details

Eric Farber-Eger

Vanderbilt University Medical Center

UNITED STATES
View details

Clara Hjalmarsson

MD PhD

Sahlgrenska universitetssjukhuset

SWEDEN
View details

Martin Nilsson

Lund University

SWEDEN
View details

Katarina Steding-Ehrenborg

Lund University

SWEDEN
View details

Ola Hansson

Lund University

SWEDEN
View details

YI-TING LIN

Karolinska Institutet

SWEDEN
View details

Kamalita Pertiwi

Lecturer/Researcher

Uppsala University

SWEDEN
View details

Martin Magnusson

Professor and senior consultant in cardiology

Skånes universitetssjukhus Lund

SWEDEN
View details

Rashmi Prasad

Associate Professor

Lund University

SWEDEN
View details

Daniel Esteban Coral Candelo

Lund University

SWEDEN
View details

Olle Melander

Professor

Lund University Medical Faculty

SWEDEN
View details

Peng Li

The University of Alabama

UNITED STATES
View details

Sébastien Thériault

Associate Professor

Laval University

CANADA
View details

Johan Ärnlöv

Karolinska Institutet

SWEDEN
View details

Ole Birger Pedersen

Professor

Zealand University Hospital

DENMARK
View details

Peter W. F. Wilson

-

UNITED STATES
View details

Mary Cushman

University Distinguished Professor

University of Vermont

UNITED STATES
View details

Louise Bennet

Lund University

SWEDEN
View details

Tove Fall

Professor

Uppsala University

SWEDEN
View details

Koichi Matsuda

University of Tokyo

JAPAN
View details

Ellen Ostenfeld

Skåne University Hospital

SWEDEN
View details

Maria F Gomez

Professor of Physiology; Director Lund University Diabetes Centre

Lund University

SWEDEN
View details

Marju Orho-Melander

Professor

Lund University

SWEDEN
View details